Literature DB >> 24682307

Interstitial lung disease in patients with hepatopulmonary syndrome: a case series and new observations.

S Shahangian1, M Y Shino, I Barjaktarevic, I Susanto, J A Belperio, M C Fishbein, T Wang.   

Abstract

Hepatopulmonary syndrome (HPS) is characterized by impaired oxygenation due to pulmonary vascular dilatation in patients with end-stage liver disease. At our center, we identified 29 patients who were listed for liver transplantation (LT) with a model for end-stage liver disease exception for HPS between 2001 and 2012. Five of these patients were found to have concurrent interstitial lung disease (ILD). The chest high-resolution computed-tomography demonstrated ground-glass opacities and subpleural reticulation, most consistent with nonspecific interstitial pneumonia (NSIP). All four of our patients who underwent LT experienced prolonged hypoxemia postoperatively, with one surgery-related death. However, the three surviving patients had eventual resolution of their hypoxemia with no evidence of ILD progression. In conclusion, we report a high prevalence of ILD, most consistent with NSIP, among patients with HPS. Although there may be increased perioperative risks, the finding of ILD in patients with HPS should not be considered an absolute contraindication to LT.

Entities:  

Mesh:

Year:  2014        PMID: 24682307     DOI: 10.1007/s00408-014-9571-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  18 in total

1.  Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation.

Authors:  Miguel R Arguedas; Gary A Abrams; Michael J Krowka; Michael B Fallon
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

2.  AASLD practice guidelines: Evaluation of the patient for liver transplantation.

Authors:  Karen F Murray; Robert L Carithers
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 3.  Inflammation and angiogenesis in fibrotic lung disease.

Authors:  Michael P Keane; Robert M Strieter; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2006-12       Impact factor: 3.119

4.  Natural history of hepatopulmonary syndrome: Impact of liver transplantation.

Authors:  Karen L Swanson; Russell H Wiesner; Michael J Krowka
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

5.  TNF-α neutralization improves experimental hepatopulmonary syndrome in rats.

Authors:  Li Liu; Nan Liu; Zhi Zhao; Jiabao Liu; Yingmei Feng; Huiqing Jiang; Delan Han
Journal:  Liver Int       Date:  2012-07       Impact factor: 5.828

6.  Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Authors:  Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

7.  Improved survival after liver transplantation in patients with hepatopulmonary syndrome.

Authors:  S Gupta; H Castel; R V Rao; M Picard; L Lilly; M E Faughnan; G Pomier-Layrargues
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

8.  Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.

Authors:  Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Utility of pulse oximetry screening for hepatopulmonary syndrome.

Authors:  Miguel R Arguedas; Harpreet Singh; Dorothy K Faulk; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-28       Impact factor: 11.382

10.  Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome.

Authors:  Eric A Collisson; Hamid Nourmand; Mark H Fraiman; Christopher B Cooper; Paul E Bellamy; Douglas G Farmer; John M Vierling; Rafik M Ghobrial; Ronald W Busuttil
Journal:  Liver Transpl       Date:  2002-10       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.